GLOW blend

GLOW is a three-peptide research blend combining GHK-Cu, BPC-157, and TB-500 in one lyophilised vial, sold strictly for research use only. Its formula varies more between shops than most blends, which makes the per-component lab data above — net content for each peptide, not just a single purity — the number that tells you what a given GLOW vial actually contains.

What is GLOW and what's actually in the vial?

GLOW is a three-peptide research blend of GHK-Cu, BPC-157, and TB-500 (Thymosin Beta-4), sold as a single lyophilised vial for research use only. Unlike most blends, its total strength and ratio vary widely between vendors — independently listed GLOW vials range from roughly 10 mg total up to 70 mg, with GHK-Cu-to-BPC-to-TB ratios from about 1:7:2 to 5:1:1. The three peptides target overlapping tissue-repair and skin pathways. GLOW is essentially the KLOW blend without KPV.

The three components, and what each contributes:

Because GHK-Cu is the dominant component by mass in most GLOW formulations, the blend leans toward skin and connective-tissue research applications — the same territory covered by the skin & anti-aging peptide category and the tissue repair category.

What does the research show for GLOW's three peptides?

No controlled clinical trial of the GLOW blend has been published as of July 2026 — every claim about the combination is extrapolated from single-compound research, most of it preclinical, and the three components differ in evidence strength. GHK-Cu has the most human-relevant record, largely from Dr. Loren Pickart's foundational copper-peptide research on collagen and wound-repair gene expression, much of it dermatological or in vitro (evidence level: preclinical and cosmetic-human). BPC-157 is supported by more than 100 preclinical studies from Prof. Predrag Sikirić's group at the University of Zagreb, beginning with the 1993 foundational paper; a 2025 orthopaedic systematic review found only one clinical study among 544 screened (evidence level: preclinical; no human RCTs). TB-500 has extensive preclinical wound-healing data and one first-in-human Phase 1 safety trial, but no efficacy RCT (evidence level: preclinical efficacy, Phase 1 safety only).

Component science is covered in the GHK-Cu science guide, the BPC-157 science guide, and the TB-500 science guide.

How does GLOW compare to KLOW and the Wolverine blend?

GLOW sits between the two-peptide Wolverine blend and the four-peptide KLOW blend: GLOW is Wolverine (BPC-157 + TB-500) plus GHK-Cu, and it is KLOW minus KPV. Adding GHK-Cu shifts the blend toward skin and collagen research; KLOW's extra KPV adds anti-inflammatory signalling. GLOW is also the least standardised of the three — Wolverine is a consistent 1:1 pairing and KLOW is usually a fixed 80 mg, while GLOW's total and ratio move considerably between vendors.

For the underlying two-peptide pairing, see BPC-157 vs TB-500.

Why is GLOW harder to verify than a single peptide?

GLOW is harder to verify than a single peptide for two reasons: a blend has no single meaningful potency number, and GLOW specifically has no standard formula. A certificate reports one whole-vial HPLC purity — how clean the material is — but that figure can read above 99% while a component is underdosed, so the verifiable signals are per-component identity (mass spectrometry confirming each peptide is present) and net content (tested milligrams versus label, for each of the three). With GLOW the net content matters even more than usual, because you cannot assume the ratio: two vials both labelled "GLOW" can carry very different amounts of GHK-Cu. Peptigrity's independent lab-test database publishes both dimensions; learn to read them in how to read peptide lab test results.

How does Peptigrity verify a GLOW vial?

Peptigrity verifies a GLOW vial through four independent measurements from an accredited third-party lab: LC-MS identity confirming GHK-Cu, BPC-157, and TB-500 are each present, HPLC-UV purity for the whole vial, per-component net content (tested versus labelled milligrams for each peptide individually), and endotoxin testing. The per-component net content is decisive for GLOW because its formula is not standardised — the only way to know a specific vial's real GHK-Cu-to-BPC-to-TB balance is to measure it. Peptigrity purchases vials anonymously at standard pricing and publishes the unedited certificate; the methodology and shop trust-score weighting are documented in how we calculate trust scores. The broader process is in the how to test peptides hub and the testing labs directory. For sourcing the dominant component specifically, see where to buy GHK-Cu.

How do you dose a blend when the formula isn't standardized?

You dose a GLOW blend by reading your specific vial's label, because the ratio you're working with is not fixed. In any blend you can only set the dose of one component — the rest follow the ratio — but with GLOW you cannot even assume that ratio from the product name, so the milligram amounts printed on your vial and its certificate are the only reliable starting point. The blend calculator converts those per-component amounts into a single reconstitution and draw. No clinical dosing protocol exists for GLOW; any figure is community-derived from single-compound research. For component-level context, see the GHK-Cu dosage guide.

What is the regulatory status of GLOW's components?

None of GLOW's three peptides is approved by the FDA or any other regulator for human use as of July 2026, and GLOW is sold strictly as a research-use-only compound. In April 2026 the FDA removed BPC-157 and TB-500 from its 503A Category 2 bulk-substances list but did not add them to Category 1, leaving them in a regulatory gray zone — neither prohibited nor authorised for pharmacy compounding, with no FDA-approved product and no USP monograph. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 and TB-500 on July 23–24, 2026, and the agency's pre-meeting briefing documents propose not adding them to the 503A Bulks List; these are advisory proposals, not final determinations. Injectable GHK-Cu sits on a separate, later review track anticipated by early 2027. BPC-157 and TB-500 are both prohibited by the World Anti-Doping Agency, so any blend containing them is banned in sport.